doi: 10.1093/pch/pxad077. eCollection 2024 May.
- PMID: 38586491
- PMCID: PMC10996578
- DOI: 10.1093/pch/pxad077
Interest in the use of medical cannabis products in children under 18 is increasing. Many medical cannabis products contain cannabidiol, delta-9-tetrahydrocannabinol, or both. Despite the many therapeutic claims, few rigorous studies guide the dosage, safety, and effectiveness of medical cannabis in clinical pediatrics. This position paper reviews current evidence and outlines recommendations for the use of medical cannabis in children. Longer term reports (two years) support the sustained tolerability and effectiveness of cannabidiol treatment in patients with Lennox-Gastaut syndrome or Dravet syndrome. Cannabis extracts enriched with cannabidiol that contain small amounts of delta-9-tetrahydrocannabinol have been evaluated in a small number of pediatric patients, and further research is needed to inform clinical practice guidelines. Given the widespread use of medical cannabis in Canada, pediatricians should be prepared to engage in open and ongoing discussions with families about its potential benefits and risks, as well as prepare individual plans. in order to monitor its effectiveness, reduce harm and limit drug interactions.
